Cisplatin plus etoposide (EP regimen) or cisplatin plus irinotecan (IP regimen) has been widely used for the treatment of unresectable neuroendocrine carcinoma, according to the guidelines for the treatment of small cell lung cancer. The response rate and median survival time were 12%-67% and 5.8-19 months for the EP regimen and 39%-83% and 10.1-14 months for the IP regimen according to previous reports, which were all retrospective analyses. The treatment efficacy of both regimens was favorable, and both regimens have been acknowledged as de facto standard regimens for unresectable neuroendocrine carcinoma. At present, a phase III trial of EP vs. IP has been planned for unresectable neuroendocrine carcinoma originating from gastrointestinal cancer and hepatobiliary and pancreatic cancer by the Japan Clinical Oncology Group (JCOG1213). In patients who were refractory or intolerant to these regimens, there are no standard regimens for use as subsequent treatments to the EP or IP regimens for unresectable neuroendocrine carcinoma. Everolimus, which is an mTOR inhibitor, has been established as a standard therapy for unresectable pancreatic neuroendocrine tumors because a significantly favorable progression-free survival was shown in a phase III trial of evelorimus vs. a placebo for aggressively progressive pancreatic neuroendocrine tumors (G1 or G2 tumors). In a subgroup analysis of this trial, everolimus showed a tendency toward a greater prolongation of progression-free survival in patients with G2 tumors than in patients with G1 tumors. In addition, the overexpression of mTOR has been reported in patients with neuroendocrine carcinoma. Therefore, everolimus is likely to be effective against neuroendocrine carcinoma. A multicenter phase II trial (NECTOR trial) is underway to elucidate the efficacy and safety of everolimus in patients with pancreatic neuroendocrine carcinoma who are refractory or intolerant to the EP or IP regimen.
rate and median survival time were 12%-67% and 5.8-19 months for the EP regimen and 39%-83% and 10.1-14 months for the IP regimen according to previous reports, which were all retrospective analyses. The treatment efficacy of both regimens was favorable, and both regimens have been acknowledged as de facto standard regimens for unresectable neuroendocrine carcinoma. At present, a phase III trial of EP vs. IP has been planned for unresectable neuroendocrine carcinoma originating from gastrointestinal cancer and hepatobiliary and pancreatic cancer by the Japan Clinical Oncology Group (JCOG1213). In patients who were refractory or intolerant to these regimens, there are no standard regimens for use as subsequent treatments to the EP or IP regimens for unresectable neuroendocrine carcinoma. Everolimus, which is an mTOR inhibitor, has been established as a standard therapy for unresectable pancreatic neuroendocrine tumors because a significantly favorable progression-free survival was shown in a phase III trial of evelorimus vs. a placebo for aggressively progressive pancreatic neuroendocrine tumors (G1 or G2 tumors). In a subgroup analysis of this trial, everolimus showed a tendency toward a greater prolongation of progression-free survival in patients with G2 tumors than in patients with G1 tumors. In addition, the overexpression of mTOR has been reported in patients with neuroendocrine carcinoma. Therefore, everolimus is likely to be effective against neuroendocrine carcinoma. A multicenter phase II trial (NECTOR trial) is underway to elucidate the efficacy and safety of everolimus in patients with pancreatic neuroendocrine carcinoma who are refractory or intolerant to the EP or IP regimen.
